BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 36189780)

  • 1. Prognostic prediction of head and neck squamous cell carcinoma: Construction of cuproptosis-related long non-coding RNA signature.
    Huang Q; You Q; Zhu N; Wu Z; Xiang Z; Wu K; Ren J; Gui Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24723. PubMed ID: 36189780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cuproptosis-related lncRNA prognostic signature for predicting treatment and immune environment of head and neck squamous cell carcinoma.
    Huan C; Gao J
    Math Biosci Eng; 2022 Aug; 19(12):12127-12145. PubMed ID: 36653989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma.
    Sun Q; Qin X; Zhao J; Gao T; Xu Y; Chen G; Bai G; Guo Z; Liu J
    Apoptosis; 2023 Feb; 28(1-2):247-262. PubMed ID: 36344660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
    Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
    Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constructing a Ferroptosis-related Long Non-coding RNA Signature to Predict the Prognostic of Head and Neck Squamous Cell Carcinoma Patients by Bioinformatic Analysis.
    Lu R; Li Z; Yin S
    Biochem Genet; 2022 Oct; 60(5):1825-1844. PubMed ID: 35098409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and validation of a prognostic signature based on seven endoplasmic reticulum stress-related lncRNAs for patients with head and neck squamous cell carcinoma.
    Zhou M; Li H; Hu J; Zhou T; Zhou L; Li Y
    Sci Rep; 2023 Dec; 13(1):22414. PubMed ID: 38104177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAs.
    Deng H; Wei Z; Du J; Shen Z; Zhou C
    Eur J Med Res; 2023 Nov; 28(1):548. PubMed ID: 38017579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma.
    Liang S; Ji L; Yu Z; Cheng Y; Gao R; Yan W; Zhang F
    Hereditas; 2024 Feb; 161(1):10. PubMed ID: 38414024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Zhu W; Ye Z; Chen L; Liang H; Cai Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Han B; Li S; Huang S; Huang J; Wu T; Chen X
    PeerJ; 2023; 11():e16197. PubMed ID: 37846311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Role of Cuproptosis in Head and Neck Squamous Cell Carcinoma Patients: A Comprehensive Analysis.
    Ding Q; Chen X; Hong W; Wang L; Liu W; Cai S; Chen X; Lu J; Qiu S
    Dis Markers; 2022; 2022():9996946. PubMed ID: 36092958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
    Front Genet; 2022; 13():947551. PubMed ID: 35938003
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
    Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
    J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
    Xu Q; Liu T; Wang J
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
    Yang L; Lu P; Yang X; Li K; Chen X; Qu S
    Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.